Data On Debrafenib & Trametinib Combo Therapy Study Testing For BRAFV600E Mutation

Zev Wainberg, M.D. Co-Director UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Hematology Oncology David Geffen School Of Medicine At UCLA Discusses Data On Debrafenib & Trametinib Combo Therapy Study Testing For BRAFV600E Mutation. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.